Welcome to our dedicated page for LBPS news (Ticker: LBPS), a resource for investors and traders seeking the latest updates and insights on LBPS stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect LBPS's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of LBPS's position in the market.
4D pharma plc (NASDAQ: LBPS) announced that it will be delisted from The Nasdaq Stock Market effective July 7, 2022, due to public interest concerns following its administration announcement on June 24, 2022. The delisting notice was issued by Nasdaq Staff based on the company's financial instability and concerns regarding the equity interests of existing shareholders. 4D pharma may appeal this decision to the Hearing Panel as per Nasdaq Listing Rule 5800 Series. The firm is known for developing Live Biotherapeutics, leveraging its proprietary MicroRx® platform.
4D pharma has announced the suspension of trading of its ordinary shares on AIM due to financial difficulties, effective from 12:30 p.m. in London. The suspension follows a demand from Oxford Finance for immediate repayment of approximately $13.86 million in outstanding loans, which the company cannot fulfill with current cash resources. Consequently, the company has entered administration, with James Clark and David Pike appointed as joint administrators. The board aims to work with the administrators on a rescue plan but acknowledges the uncertainty of success.
4D pharma plc (NASDAQ: LBPS) announced the presentation of a Phase II clinical trial poster for MRx0518 in combination with BAVENCIO® at the 2022 ASCO Annual Meeting. This trial aims to evaluate MRx0518's safety and its effect on progression-free survival in patients with unresectable locally advanced or metastatic urothelial carcinoma who have not progressed after platinum-containing chemotherapy. The study will enroll 30 patients and assess various efficacy measures alongside collaboration with Merck KGaA and Pfizer Inc.
4D pharma plc (NASDAQ: LBPS), a leader in Live Biotherapeutic products, announced that CEO Duncan Peyton will present at the H.C. Wainwright Global Investment Conference on May 24, 2022, starting at 7:00 a.m. ET. The presentation will be available for on-demand viewing on the company's website for 90 days. 4D pharma specializes in the development of drugs derived from the microbiome, utilizing its proprietary MicroRx® platform. The company has five clinical programs, including studies in solid tumors and asthma, and is poised to initiate Phase I trials on additional candidates.
4D pharma plc (NASDAQ: LBPS) has presented a late-breaking poster on the Phase I/II trial data for MRx-4DP0004, a Live Biotherapeutic product for asthma treatment, at the American Thoracic Society Conference in San Francisco, CA. The treatment demonstrated safety and tolerability, with no severe adverse events reported. Efficacy results showed 83.3% of treated patients improved their Asthma Control Questionnaire scores compared to 56.3% on placebo. The trial is now moving to Part B to evaluate MRx-4DP0004 in more symptomatic asthma patients, aiming to further validate its therapeutic potential.
4D pharma plc (NASDAQ: LBPS) announced its 2021 financial results and highlighted key objectives for 2022. The company reported cash and cash equivalents of $21.0 million and a net loss of $32.1 million for the year. Significant operational milestones included clinical trial advancements for MRx0518 and Blautix® in oncology and irritable bowel syndrome, respectively. 4D pharma completed a merger with Longevity Acquisition Corporation, enhancing its visibility in US capital markets. Looking ahead, 4D pharma anticipates multiple clinical trial initiations in 2022.
4D pharma plc announced that the renal cell carcinoma (RCC) group in Part B of its study for MRx0518, in combination with KEYTRUDA®, met its primary efficacy endpoint early. Out of 20 enrolled RCC patients, 4 achieved a clinical benefit, indicating stable disease for over six months. The study aims to explore MRx0518's effectiveness in ICI-refractory tumors and is part of a larger Phase I/II trial including other tumor types. The company plans to hold a conference call to discuss these interim results.
4D pharma plc (NASDAQ: LBPS) announced that CEO Duncan Peyton and CSO Alex Stevenson will participate in a fireside chat at the Chardan Metagenomics and Microbiome Medicines Summit on March 1, 2022, at 9:00 a.m. ET. The chat will be available for live streaming on the company's website, with replays accessible for 90 days.
4D pharma is a pioneer in developing Live Biotherapeutics—drugs derived from the microbiome. The company has five clinical programs including studies on MRx0518 and Blautix® focusing on various cancers and irritable bowel syndrome.
4D pharma plc has received FDA IND clearance for two Live Biotherapeutics, MRx0005 and MRx0029, targeting Parkinson’s disease. This marks the first time a Live Biotherapeutic has been approved for Parkinson's treatment in the U.S. The company plans to initiate a Phase I clinical trial in mid-2022. These therapeutic candidates have shown promise in pre-clinical studies, potentially addressing neuroinflammation and gut barrier integrity. The collaboration with Parkinson's UK enhances their patient-focused approach.
4D pharma plc announced positive results from Part A of its Phase I/II trial of MRx-4DP0004, a Live Biotherapeutic for asthma treatment. The primary endpoint of safety and tolerability was achieved, with a lower rate of adverse events in MRx-4DP0004 patients compared to placebo. Positive trends were observed across multiple secondary endpoints, including improved asthma control and reduced reliance on rescue medication. The trial's next phase will involve up to 90 patients to assess clinical efficacy and biomarkers. A conference call is scheduled for
